Koreanische Wissenschaftler entwickelten orale Medikamente gegen Covid-19-Randomisierte, doppelblinde, placebokontrollierte klinische Studie mit 300 Patienten, dass CP-CoV03 die CoVID-19-Symptome über 48 Stunden ohne schwerwiegende unerwünschte Ereignisse wirksam war.

I’ve linked to the news release in the post above. In this comment, for those interested, here’s the link to the peer reviewed journal article:

https://www.nature.com/articles/s41467-025-62423-4

From the linked article:

Korean scientists say they developed oral drug against COVID-19

A group of scientists, primarily from South Korean universities, has confirmed the efficacy of an oral anti-viral treatment, called CP-COV03 or Xafty, against COVID-19 after a clinical trial.

Developed by Korea’s biotech company Hyundai Bioscience, the drug was found to address major COVID-19 symptoms listed by the U.S. Food and Drug Administration, including cough, headache, sore throat, nausea and chills.

The findings were published in the latest edition of the peer-reviewed journal Nature Communications.

„We conducted a randomized, double-blind, placebo-controlled clinical trial with 300 patients to learn that CP-COV03 was effective in improving COVID-19 symptoms for more than 48 hours, with no serious adverse events,“ Dankook University professor Choy Jin-ho told UPI. He is one of the paper’s corresponding co-authors.

„Patients treated with CP-COV03 returned to usual health more quickly and had a lower risk of hospitalization compared to the control group. This shows that the drug is safe and effective in patients suffering from mild to moderate COVID-19,“ he said.